Merck Animal Health shared earlier this week that the FDA approved its atinvicitinib tablets (NUMELVI; Merck Animal Health), a once daily, first line treatment for canine patients 6 months and older ...
The Board and Train program addresses anxiety, reactivity, and socialization gaps that affect nearly half of all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results